Key Spec Table
|Species Reactivity||Key Applications||Host||Format||Antibody Type|
|Fg, B, H, R||IH(P)||M||FITC||Monoclonal Antibody|
|Description||Anti-Cytokeratin Pan Antibody, clone C11, FITC conjugated|
|Safety Information according to GHS|
|Storage and Shipping Information|
|Storage Conditions||Store at +4°C protected from light. DO NOT FREEZE. For long term use and storage aliquot conjugate into small volumes and store at +4°C.|
|Material Size||100 assays|
|Reference overview||Pub Med ID|
|Effects of tissue fixation conditions and protease pretreatment on immunohistochemical performance of a large series of new anti-keratin monoclonal antibodies: value in oncopathology. |
Bártková, J, et al.
Neoplasma, 38: 439-46 (1991) 1991
|A series of 14 new monoclonal antibodies to keratins: characterization and value in diagnostic histopathology |
Bartek, J. et al.
J. Pathol., 164:215-224 (1991) 1991
|Use of keratin antibodies in tumor diagnosis. |
Lane, E B and Alexander, C M
Semin. Cancer Biol., 1: 165-79 (1990) 1990
The tissue specific expression shown by intermediate filament proteins, their ease of extraction and their antigenicity has led to the use intermediate filament antibodies in diagnostic pathology, particularly antibodies to keratin intermediate filaments because of the predominant involvement of epithelia in cancers. We review the principles of differentiation-specific keratin expression and detail 100 of the best-known monoclonal antibodies to keratins which are currently in use: in many circumstances antibodies can now be reliably used as in situ markers of keratin expression. We also suggest a database scheme for better dissemination of information on available monoclonal antibodies to keratins in the future.
|Patterns of expression of keratin 19 as detected with monoclonal antibodies in human breast tissues and tumours. |
Bartek, J, et al.
Int. J. Cancer, 36: 299-306 (1985) 1985
|Anti-Cytokeratin Pan, Clone C-11, FITC Conjugated - Data Sheet|